• Chief Medical Officer at Longboard Pharmaceuticals
Dr Randall Kaye has over 30 years of experience in the medical field and has served as Chief Medical Officer since March 2022. Prior to joining Longboard, Dr Kaye was Chief Medical Officer of Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions. Prior to Neurana, he served as Chief Medical Officer of Click Therapeutics, Inc, a leader in digital healthcare innovation, where he was involved in the development of software as a prescription medical treatment for a number of chronic debilitating conditions. Prior to Click, he served as Chief Scientific Officer of SSI Strategy Holdings LLC, where he oversaw clinical development, medical affairs and pharmacovigilance. In conjunction with his role at SSI Strategy, he served as Chief Medical Officer of Axsome Therapeutics, Inc. Earlier in his career, Dr Kaye held the positions of Chief Medical Officer of Avanir Pharmaceuticals, Inc, which was acquired by Otsuka Pharmaceutical Co, and Vice President, Medical Affairs of Scios Inc and InterMune, Inc. He also held clinical development and medical affairs positions at Pfizer Inc. Dr Kaye earned an MD, MPH and BS at George Washington University, completed his pediatric training at UMASS Medical Center and finished his academic training as a postdoctoral Research Fellow at Harvard Medical School.
